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Background: Clostridium difficile is an opportunistic human intestinal pathogen, and C. difficile infection (CDI) is one
of the main causes of antibiotic-induced diarrhea and colitis. One successful approach to combat CDI, particularly
recurrent form of CDI, is through transplantation of fecal microbiota from a healthy donor to the infected patient.
In this study we investigated the distal gut microbial communities of three CDI patients before and after fecal
microbiota transplantation, and we compared these communities to the composition of the donor’s fecal microbiota.
We utilized phylogenetic Microbiota Array, high-throughput Illumina sequencing, and fluorescent in situ hybridization
to profile microbiota composition down to the genus and species level resolution.
Results: The original patients’ microbiota had low diversity, was dominated by members of Gammaproteobacteria and
Bacilli, and had low numbers of Clostridia and Bacteroidia. At the genus level, fecal samples of CDI patients were rich in
members of the Lactobacillus, Streptococcus, and Enterobacter genera. In comparison, the donor community was
dominated by Clostridia and had significantly higher diversity and evenness. The patients’ distal gut communities were
completely transformed within 3 days following fecal transplantation, and these communities remained stable in each
patient for at least 4 months. Despite compositional differences among recipients’ pre-treatment gut microbiota, the
transplanted gut communities were highly similar among recipients post-transplantation, were indistinguishable from
that of the donor, and were rich in members of Blautia, Coprococcus, and Faecalibacterium. In each case, the gut
microbiota restoration led to a complete patient recovery and symptom alleviation.
Conclusion: We conclude that C. difficile infection can be successfully treated by fecal microbiota transplantation and
that this leads to stable transformation of the distal gut microbial community from the one abundant in aerotolerant
species to that dominated by members of the Clostridia.
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The use of antibiotics in modern medicine has led to a sig-
nificant inhibition and in some cases complete eradication
of many infectious agents that threaten human population
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unless otherwise stated.antibiotic use is also linked to an increase in the inci-
dence of antibiotic-associated intestinal disease. Many
of these incidents are caused by Clostridium difficile, an
opportunistic human intestinal pathogen from class
Clostridia. Clostridium difficile infection (CDI) is
known to have a range of manifestations, from mild
diarrhea to fulminant colitis, toxic megacolon, and
death. The disease often manifests itself after treatment
with antibiotics and the associated loss of resident
microbiota in the intestine. Resistance of C. difficile to
many classes of antibiotics and its ability to form spores
allows this bacterium to survive antibiotic administrationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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commensals in the gut creates conditions favorable for a
subsequent overgrowth of this opportunistic pathogen [2].
C. difficile spores are often acquired nosocomially, and as
a result, a high incidence of CDI is seen among hospital-
ized patients, in the outpatient community, and among
nursing home residents [3,4]. Other reservoirs of CDI can
also exist according to a recent report [5].
Because of the resistance of C. difficile spores to antibi-
otics, it is challenging to cure CDI with antibiotic adminis-
tration. Among alternative strategies, fecal microbiota
transplantation (FMT) is gaining a wider acceptance as
treatment for recurrent CDI. In this technique, fecal
microbiota obtained from a healthy donor is processed,
standardized, and subsequently transplanted into patients
suffering from the recurrent C. difficile infection. FMT is
highly successful (>90% success rate) and CDI symptoms
often resolve within days of the transplantation procedure
[6,7]. Recent studies from our group showed that the eradi-
cation of the disease symptoms is accompanied by a dra-
matic shift in the microbial community as examined by
TRFLP and gene sequencing analyses [8,9]. However, these
methods were limited in the achieved taxonomic reso-
lution and the ability to directly quantify microbiota mem-
bers, and thus they could not reveal detailed microbiota
composition before and after FMT treatment.
In this study we used a human intestinal microbiota-
specific phylogenetic Microbiota Array [10-13] to measure
phylotype- and genus-level changes in gut microbiota of
three CDI patients who underwent an FMT procedure.
Microbiota Arrays contain probes targeting full-length
16S rRNA genes of 775 human microbiota phylotypes and
allows direct comparison of taxon abundances between
samples [10]. The microarray data were corroborated with




All patients suffered from multiple recurrent C. difficile
infection (CDI) refractory to clearance by standard anti-
biotic therapies, as defined previously [14]. The study of
their fecal microbiota before and after FMT was approved
by the University of Minnesota Institutional Review Board
and all patients provided informed consent to participate
in this study.
FMT procedure
The FMT was performed using a standardized preparation
of concentrated fecal microbiota as previously described
[14]. Criteria for the selection of donor were described in
detail previously [9,14]. The same donor was used for all
recipients, but individual donations were collected on dif-
ferent days. Briefly, 50 g of fecal material were mixed with250 mL of sterile phosphate buffered saline (PBS). The
feces were blended, sieved, and the resulting suspension
was centrifuged and washed in PBS. Patient 1 received
freshly prepared material, while frozen lots were used for
patients 2 and 3. We previously demonstrated FMT
success with frozen fecal microbial suspension to be com-
parable to that obtained with a fresh preparation [14]. The
patients were treated with 125 mg vancomycin, four times
daily by mouth, until 2 days prior to the procedure. The
day before the procedure, patients received a split dosage
polyethylene glycol-based purgative (GoLYTELY®) to
remove residual antibiotic and fecal material. FMT was
performed via colonoscopy as previously described [14].
Sample collection
Patient fecal samples were collected at home by the pa-
tients and stored frozen at approximately -20°C. The first
sample for each patient was collected while the patient
was receiving oral vancomycin (125 mg, four times per
day) during the period up to the FMT. Samples were
transferred to the laboratory within 1 week of collection
and stored at -80°C until used. Donor samples for DNA
extraction were collected during processing of material for
FMT, and stored frozen at -80°C until used. A timeline
showing sample collection for the three patients involved
in this study is shown in Figure 1A.
Isolation of genomic DNA and hybridization to Microbiota
Array
Total genomic DNA (gDNA) was isolated from fecal ma-
terial using ZR Fecal DNA Isolation kit (Zymo Research
Corporation, procedure incorporates bead beating) ac-
cording to manufacturer’s protocol. The full length bacter-
ial 16S rRNA gene was amplified from genomic DNA
with degenerate primers Bact-27Fv4 (5′-AGRGTTYGA
TYMTGGCTCAG-3′) and Univ-1492Rv1 (5′-GGHTA
CCTTGTTACGACTT-3′) [10,15]. Four separate PCR
reactions were pooled together, fragmented, and then
hybridized to Microbiota Array. Microbiota Array is based
on Affymetrix, Inc., platform and contains sets of phylo-
genetic 16S rRNA gene probes (25-mer probes, 5 to 11
probe pairs in each set, each probe pair consists of perfect
match and mismatch probes, each set interrogates a separ-
ate phylotype) allowing detection and enumeration of 775
bacterial phylotypes of human intestinal microbiota [10].
Microarray hybridization, washing, and scanning were
carried out as described previously [12,16].
Microarray data analysis
Raw microarray data were analyzed using previously devel-
oped pipeline [12]. Specifically, to obtain phylotype detec-
tion calls, the raw data were processed with standard MAS5
detection algorithm (Affymetrix, Inc.) using α1 = 0.03 and
α2 = 0.05 parameter values. MAS5 algorithm is based on
Figure 1 Changes in microbiota diversity and composition following fecal transplantation in CDI patients. Microbiota communities were
profiled from three CDI patients, healthy donor, and from each patient over a 4-month period following fecal transplantation. Samples were
collected periodically as shown in (A). Community diversity and evenness were assessed by calculating the Shannon H’ (diversity, B) and Simpson
E (evenness, C) indices based on microarray phylotype abundance data. Community structure in each sample is shown at class level in (D) (distribution
is based on microarray data) and (E) (distribution is based on sequencing data). Missing data represent samples that had lower amount of fecal
material available; thus not all analyses could be carried out for these samples.
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mates for each phylotype, raw data were first normalized in
CARMAweb utilizing MAS5-VSN-MAS5-MedianPolish
procedure as we did previously [10]. The normalized
phylotype signal values were adjusted for estimated
cross-hybridization rate and unequal 16S rRNA gene
copy number as described [12]. To assess our ability to
separate samples based on their microbial phylotypecomposition, principal components (PCA) and phylo-
genetic principal coordinates (PCoA) analyses were
used [13]. PCA, alpha diversity calculations, and per-
mutation analyses were performed in Matlab (The
Mathworks, Inc.) by employing custom written scripts.
PCoA analyses were carried out on the Fast UniFrac
web server [17]. Separation of genera into clusters ac-
cording to genus abundances among samples was based
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to separate genera displaying patient-specific patterns of
abundance changes.
High-throughput amplicon sequencing and data analysis
DNA extractions were done as previously described [9]
using MOBIO PowerSoil DNA extraction kits (MOBIO,
Carlsbad, CA, USA), according to the manufacturer’s
instructions. Fecal DNA samples were used as template in
PCR amplification reactions of the V6 hypervariable region
of the 16S rRNA gene. All PCR reactions used 25 ng of
fecal DNA as template and were performed in triplicates.
DNA and amplicon preparation for high-throughput
sequencing were carried out as described [9]. The samples
were sequenced using Illumina Hiseq 2000 sequencer fol-
lowing the manufacturer’s protocols (Illumina, Hayward,
CA, USA). Paired-end sequences were generated (100 nt
read length) with one to three pooled samples per lane
following Illumina multiplexing protocols. Paired ends
were merged using a custom C script [9] by employing a
minimal overlap of 25 nucleotides with 98% identity.
Sequence data were processed and analyzed using the
MOTHUR program [18]. Merged sequences were binned
into individual sample sets according to the six nucleotide
barcode sequences. The list of barcodes used and primers
is provided in Additional file 1: Table S1. Sequence reads
containing ambiguous bases, homopolymers larger than
seven nucleotides, more than one mismatch in the primer
sequence, or an average per base quality score below 25
were removed. Primer and barcode sequences were
trimmed from the sequence reads prior to analysis.
Sequences that only appeared once in the total set were
assumed to be a result of sequencing error and were
removed from the analysis. Sequences that were flagged as
likely chimeras using the UCHIME algorithm were also
removed from the analysis. Sequences were clustered into
OTUs using the furthest neighbor algorithm with a 90%
cutoff [19]. Taxonomic assignment was done using the
Bayesian method with a 100 iteration bootstrap algo-
rithm and a probability cutoff of 0.60 [9]. Summary of
the obtained reads and OTU assignments are provided
in the Additional file 2: Table S2. The complete se-
quence dataset is available in the SRA archive under
bioproject number PRJNA238486 and metadata are pre-
sented in Table S6.
Fluorescent in situ hybridization (FISH)
FISH was carried out as we did previously [11]. Clostridia,
Bacteroidia, and Proteobacteria were visualized using
FITC-labeled probes Clept1240 (5′-GTTTTRTCAACGG
CAGTC-3′) + Erec482 (5′-GCTTCTTAGTCARGTACC
G-3′), Bac303 (5′-CCAATGTGGGGGACCTT-3′), and
Prot612 (5′-TTCCCVGGTTRAGCCCKGG-3′), respectively
[11]. Following a previously optimized sample preparationprotocol [11], cells were visualized under Nikon TE2000-S
fluorescent microscope. In order to conduct valid com-
parisons between FISH and microarray results, micro-
array data were adjusted to account for the inability of
FISH probes to detect certain genera of Clostridia and
Bacteroidia (see [11] for details).
Results
Outcomes of the FMT procedure
We profiled intestinal microbiota in fecal samples collected
from (1) three CDI patients before the FMT procedure,
from (2) healthy donor, and from (3) each CDI patient over
a period of 4 months following the FMT procedure.
Samples were collected from each CDI patient a few
days before the transplantation, on days 3 and 7 after
transplantation, and then periodically with gradually in-
creasing time periods between sample collections based
on patients’ availability and ability to provide a fresh
stool sample (Figure 1A). Clinically, all three CDI pa-
tients had reduced diarrheal symptoms within several
days after the FMT. All patients were documented to
have undetectable C. difficile toxin B at 2 months by
qPCR. Patients 1 and 3 had a firm bowel movement on
day 3 and remained free of C. difficile infection for 2.5
and 2.0 years, respectively. Patient 2 had underlying ul-
cerative colitis, which decreased from severe pancolitis
to moderate disease as evidenced by endoscopic and
histological criteria 1 month after FMT. Clinically,
bowel movement frequency decreased from 10-12/day
to 4/day, and rectal bleeding and tenesmus resolved.
Colonoscopy at 1 year showed endoscopically moderate
disease in the distal colon, but near normal appearance
in the proximal colon. This patient remained free of
C. difficile infection for 1.5 years until treated with
antibiotics for a urinary tract infection, at which time
he experienced a re-infection with C. difficile.
Changes in distal gut microbial community composition
in CDI patients following fecal transplantation
The microarray phylotype abundance data were used to
assess the differences in the intestinal microbial communi-
ties among all samples. The ecological organization of the
communities was calculated using the Shannon’s diversity
(Figure 1B) and the Simpson’s evenness (Figure 1C) indi-
ces. Overall, the gut microbiota in CDI patients had low
diversity and evenness in all three patients prior to FMT
(Shannon’s H’ = 2.58 ± 0.09 and Simpson E = 0.11 ± 0.03).
The communities were dominated by relatively few mem-
bers with high abundance, and the overall number of spe-
cies in the community was low. In contrast, the microbiota
from the healthy donor showed statistically significantly
higher diversity and evenness (H’ = 4.73 ± 0.02 and E =
0.24 ± 0.01; α < 10−5 and α = 0.001, respectively, based on a
one-tail T-test). After-transplantation samples from day 3
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those of the donor microbiota (H’ = 4.61 ± 0.14 and E =
0.25 ± 0.02; α = 0.18 and α = 0.74 based on a two-tail T-test
of donor and after-FMT sample comparison). Similar ef-
fects of microbiota transplantation (delivered as duodenal
infusion) on gut microbial diversity in CDI patients were
also recently observed by van Nood and co-workers [7].
The overall community structure remained remarkably
stable through the 4-month sampling period (average
Spearman correlation of microarray-determined genus
abundances between consecutive time points was 0.87 for
after transplantation samples) and at the end of the ob-
servation both community diversity and evenness
remained similar to that of the donor (H’ = 4.71 ± 0.05
and E = 0.26 ± 0.02).
At the class level, microarray results revealed consider-
able changes between the microbiota profiles before and
after transplantation (Figure 1D and Additional file 3:
Table S3). In all three CDI patients, their fecal samples
before transplantation contained relatively high abun-
dance of organisms belonging to classes Gammaproteo-
bacteria (40.9% cumulative abundance on average) and
Bacilli (34.5% on average). Donor samples were domi-
nated by the classes Clostridia (74.5%), Actinobacteria
(10.0%), Erysipelotrichi (5.6%), and Bacteroidia (4.3%).
Concordantly, the recipients’ after-transplantation sam-
ples showed increases in Bacteroidia (from 0.5% to 6.1%
on average) and Clostridia (from 16.1% to 75.5%), with
Proteobacteria (2.1%) and Bacilli (2.0%) in low abun-
dance. The microarray class level data also indicated an
overall stability of the microbial community structure in
the after-transplantation distal gut over the entire
follow-up period (Figure 1D). The dramatic shifts in theFigure 2 Separation of samples based on ordination multivariate analysi
analysis (PCA, A) and unweighted (separation is based on phylotype presence,
abundance, C) principal coordinates analysis (PCoA) show separation of recipie
obtained after transplantation. Percent of dataset variability explained by eachabundances of microbial classes following FMT were
also evidenced by Illumina sequencing (Figure 1E), al-
though the sequencing results showed somewhat greater
community variability among the after-transplantation
samples. The observed greater robustness of microarray
data is likely explained by the ability of microarray to
measure presence and abundance of each interrogated
phylotype in each sample [12]. Thus, the microarray results
are not dependent on the sequencing depth and are less
sensitive to any 16S rRNA gene PCR amplification biases.
Utilizing phylotype abundance data obtained with
Microbiota Array, sampled microbial communities were
also analyzed with high-dimensionality reducing principal
components analysis (PCA) and phylogenetic principal
coordinates analysis (PCoA) ordination approaches [13].
All ordination analyses showed a clear separation of recip-
ients’ before-transplantation samples from those of the
donor and the patients’ after-transplantation samples
(Figure 2). Consistent with our analysis as described
above, there was a considerable difference in the com-
munity phylotype structure between the CDI and donor
samples, and this difference was the largest determinant
of dataset variability, because the donor and CDI sam-
ples were separated along the principal component/coord-
inate 1 axis representing the highest data variability [20]. A
significant degree of variability was seen among the recipi-
ents before transplantation especially in the phylotype
presence (Figure 2B), indicating that pre-transplantation
gut microbial communities were unique to each profiled
CDI patient. The after-transplantation samples for all three
recipients clustered together with donor samples, demon-
strating that compositional individuality of pre-treatment
gut microbiota had little influence on the post-FMTs of microarray phylotype abundance data. Principal components
B) and weighted (separation is based on phylotype presence and
nt samples before transplantation from both donor and recipient samples
principal component/coordinate is shown in brackets in axis titles.
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microbiota structure was thus determined by donor micro-
biota community.Visualization of fecal microbiota with FISH
Because fluorescent in situ hybridization allows cell
quantitation through direct visualization, it is a good
choice for validation of results obtained through DNA-
based techniques such as phylogenetic microarrays or
high-throughput sequencing. With that goal, we utilized
FISH to visualize and quantify Bacteroidia, Clostridia,
and Proteobacteria in three fecal samples from CDI set
1: recipients before transplantation, donor, and samples
obtained from the same patient 3 days after transplant-
ation. As shown in Figure 3A, the taxon abundances
obtained from FISH quantitation matched well those from
the microarray results, with only somewhat higher estimate
of Proteobacteria in the recipient pre-transplantation sam-
ple based on FISH (28.8% and 41.0% based on array and
FISH calculations, respectively, note that microarray data
were adjusted to match each FISH probe inability to detect
some members of each class/phylum). A representative
image from each sample examined by FISH using a Proteo-
bacteria probe and a generic DNA stain (DAPI) are shown
in Figure 3B; Proteobacteria cells were largely detected only
on a slide with initial recipient microbiota but not in the
other two samples.Figure 3 Quantification of bacterial abundances using
fluorescent in situ hybridization. Select fecal samples from CDI set 1
were profiled using class specific DNA probes as shown. (A) A
comparison of class relative abundances measured by Microbiota Array
and by FISH. (B) Representative captured image from each sample
visualized with Proteobacteria fluorescent probe (green color) and
DAPI DNA stain (blue color).Specific genera are responsible for observed microbiota
differences among samples
Because Microbiota Arrays contain probes to individual
microbial phylotypes, its use allowed a quantitative
assessment of phylotype and genus level abundances in all
samples. We thus sought to compare genus abundances
among samples and to define groups of genera that
displayed similar patterns across the sample set. Genera
were distributed into five groups based on their abundance
values among samples (Figure 4, Additional file 4: Figure S1,
and Additional file 5: Table S4). Group 1 comprised genera
that were present at high abundance in the donor and after-
transplantation samples but which were not highly abundant
in CDI patients’ samples prior to FMT procedure. Notable
members included a number of genera from the classes
Clostridia and Bacteroidia, such as Bacteroides, Blautia,
Coprococcus, Faecalibacterium, Papillibacter, and Roseburia.
These taxa are known to comprise a substantial portion of
human colonic microbiota and to play important roles in the
energy metabolism and commensal host-microbial inter-
actions [21]. Among these, only Blautia and Coprococ-
cus were also somewhat abundant in the patient before-
transplantation samples (Figure 4, group 1).
Group 2 consisted of five facultatively anaerobic and/or
aerotolerant genera Enterobacter, Escherichia, Lactobacillus,
Raoultella, and Veillonella; these were present at high abun-
dance in all three before-transplantation samples, but not in
donor samples. The levels of these genera were similarly low
in the fecal samples of CDI patients after FMT. Genera that
we assigned to group 3 were abundant in some but not all
before-transplantation samples, while their levels in donor
and after-transplantation samples were similarly low. These
included Streptococcus (abundant in patients 1 and 2),
Zymophilus and Klebsiella (abundant in patients 2 and 3),
Haemophilus (only found in patient 1), and Enterococcus
(only in patient 3). Two genera - Bifidobacterium and Lacto-
coccus - did not show consistent patterns across donor,
before-, and after-transplantation samples and were thus
assigned to group 4.
Group 5 comprised genera that were not consistently
detected in samples or detected with very low abundance
(N = 86, see Additional file 4: Figure S1). Similar to the find-
ings shown in Figure 1, genera present in high abundance
in the donor samples were also highly abundant in the
after-transplantation samples. Conversely, genera present in
high abundance in all or some of the recipient before-trans-
plantation samples were in relatively lower abundance in
both the donor and after-transplantation samples. This
indicates a complete reorganization of the gut microbiota
in CDI patients following FMT procedure.
Species level changes following FMT
The distribution of phylotypes and species generally
followed the pattern observed for genera, with species of
Figure 4 Relative abundances of bacterial genera in all samples as measured by Microbiota Array. All genera were distributed into
groups based on the analysis of genus abundances across samples. A group of genera that were not detected consistently in samples or were
detected at very low level is not shown (N = 86). A heat-map of genus abundances is shown on the left-hand side of the image. Gradient color
scheme and phylum designation are displayed in the legend. An average abundance of all genera in each type of samples is shown for groups 1
and 2 on line graphs on the right-hand side. For groups 3 and 4, the line graphs display individual genus values. The abundances of after-treatment
time points were averaged together. Where possible, error bars were calculated to represent standard error of the mean.
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in pre-FMT samples but abundant in donor and after-
FMT samples. While microarray allows enumeration of
775 different microbial phylotypes, only about 65 of
them are assigned to known microbial species [10].
Among these, Bacteroides fragilis, B. ovatus, and B. uni-
formis were not present above 0.1% abundance level in
any of the original patient samples, but increased to an
average cumulative abundance of 1.9% after transplant-
ation. Similar increases in after-FMT samples were ob-
served for Faecalibacterium prausnitzii, Clostridium
bartlettii, Dorea longicatena, Holdemania filiformis,
Roseburia intestinalis, and Ruminococcus obeum. Inter-
estingly, even though the microarrays contained a
probe-set for Clostridium difficile, this species was not
confidently detected in any of the original CDI patients’
fecal samples, possibly because the vegetative C. difficile
cells were largely eradicated by antibiotic treatment,
whereas DNA isolation from C. difficile spores might
not have been successful [22]. Concordantly, C. difficile
toxin B was also not detected in these samples with clinical
qPCR test. In contrast, individual patient’s pre-
transplantation samples contained remarkably high
abundance levels of a few other species: - Bifidobacterium
adolescentis (12.8% of overall abundance) and Escherichia
coli (3.5%) in patient 1, Klebsiella pneumonia (5.5%) andBifidobacterium adolescentis (3.1%) in patient 2, and
Enterococcus faecium (17.1%), Lactobacillus salivarius
(6.7%), and Escherichia coli (3.3%) in patient 3.
Discussion
The goal of this study was to profile phylotype-level micro-
biota composition in three CDI patients and to follow
microbiota changes during and after FMT. While several
previous reports have evaluated microbiota alterations
following FMT therapy in human patients [7-9,23,24], the
genus and species level changes were explored only in few
studies [25]. The utilization of phylogenetic Microbiota
Array allowed us to obtain quantitative measurements of
different taxonomical groups in all samples, and micro-
arrays uniquely generated genus and species level reso-
lution of distal gut microbiota in these samples. We used
Illumina high-throughput sequencing and FISH to provide
additional support for our findings.
The analyses presented here show that the colon of each
CDI patient was host to a severely compromised intestinal
microbial community, which was significantly reduced in
diversity and richness. This was likely a result of C. difficile
proliferation as well as due to the antibiotic treatment
used in an attempt to rid the disease. Ulcerative colitis, a
common coexisting condition in patients with recurrent
CDI [14,26], may have contributed to dysbiosis in patient
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nificantly decrease microbial diversity [27]. While the
healthy gut microbiota is usually dominated by Clostridia
and Bacteroidia, fecal samples of the CDI patients were
abundant in Gammaproteobacteria and Bacilli. Interest-
ingly, both of these abundant taxons contain many facul-
tative anaerobic or aerotolerant bacteria, and many are
known to be abundant in the human ileum, in part due to
their ability to tolerate the presence of oxygen [28-33].
Normally such species contain genes coding for proteins
that allow cells to ameliorate toxic reactive oxygen species
(ROS), such as hydrogen peroxide and superoxide O2
−. In
addition to the tolerance against molecular oxygen and its
effects, these oxidative stress response genes also provide
protection against ROS generated by neutrophils and
macrophages and released into the gut during inflamma-
tion [34]. We found the presence of at least two of four
genes coding for either catalase (decomposes hydrogen
peroxide), superoxide dismutase (detoxifies superoxide),
glutathione synthase (glutathione serves as antioxidant),
or glutathione peroxidase (reduces hydrogen peroxide to
water) in the genome sequences of human gut repre-
sentatives of Enterobacter, Escherichia, Lactobacillus,
Veillonella, Klebsiella, Haemophilus, Enterococcus, and
Streptococcus (see Additional file 6: Table S5). These
genera were found to be highly abundant in the fecal
samples of CDI patients, an observation partially
matched by the analysis of CDI microbiota by Anthra-
ham and colleagues [35]. In contrast, the genomes of
several prominent obligate anaerobes from the human
gut such as Faecalibacterium prausnitzii and Roseburia
intestinalis did not contain any of these genes.
We offer three potential explanations for the observed
composition of the fecal microbiota in CDI patients. 1)
Because C. difficile infection is associated with frequent
diarrhea, it usually leads to a significantly shortened
transit time in the large intestine [36], and diarrhea
would result in a lower overall load of microbes in the
colon [37]. This may cause significantly fewer members
of the colonic communities being present in the fecal
material, and as a consequence it will lead to an increase
of relative abundances of small intestinal genera in feces
(these can be shed in higher amounts into the colonic
lumen due to faster gut transit time). 2) Because diar-
rhea in combination with antibiotic administration dur-
ing standard CDI treatment are expected to reduce the
overall counts of microbes in the colon [38], this may in-
crease the average oxygen level in that gut region (typic-
ally less than 1% [39]). Additionally, reactive oxygen
species can be released in the gut of CDI patients by
macrophages and neutrophils, which are recruited into
gut mucosa during CDI development [40]. Both of the
described effects will create an environment selectively
more advantageous for the species that are able to toleratethe presence of oxygen and ROS. 3) Antibiotic administra-
tion alone can play a role in shaping the composition of
the intestinal microbial community. A standard antibiotic
regimen in CDI included metronidazole followed by mul-
tiple cycles of vancomycin, and patient 2 also received
rifaximin. Since metronidazole predominantly targets an-
aerobic bacteria [41], and vancomycin inhibits cell wall
synthesis of gram-positive bacteria [42], the use of these
antibiotics would be expected to reduce members of class
Clostridia (most are strictly anaerobic gram-positive
species) and not affect Proteobacteria (many are facul-
tatively anaerobic gram-negative species). It is likely
that a combination of the factors described impart a se-
lective pressure on the gut microbial communities in
CDI patients. This in turn likely leads to a relative de-
crease in the abundance of obligate anaerobic species
and an increase in the presence of aerotolerant mem-
bers in the distal gut and fecal matter.
In contrast to the fecal communities of CDI patients, the
fecal samples of the donor were dominated by members of
Clostridia, Actinobacteria, Erysipelotrichi, and Bacteroidia,
which is a common composition of the distal gut micro-
biota in healthy humans [43]. The FMT procedure rapidly
and drastically altered the intestinal microbiota communi-
ties in CDI patients, both in the taxonomy of organisms
present and in their relative abundances, so that even at
day 3 after FMT the recipient’s microbiota matched that of
the donor. Such microbiota restructuring after FMT was
also noted in our previous reports as well as in several
other studies [8,9,24,44]. Genus and species level changes
in CDI patients upon FMT were also reported by Shahinas
and colleagues, though the success of community
reorganization varied from case to case in that study [25].
In all our patients, the composition of these engrafted
communities remained stable over the 4-month observa-
tion period, and the structure of the microbiota depended
upon the original composition of the donor community.
This microbial compositional shift was accompanied by
the cessation of CDI symptoms.Conclusion
Several reports have indicated the overwhelming clinical
efficacy of FMT [7,14,45,46]. In contrast to probiotic ther-
apy, which introduces a limited number of micro-
organisms into the intestinal tract, FMT effectively replaces
the entire colonic microbiota with a healthy one in order
to reestablish the lost intestinal homeostasis. The success
of FMT to treat C. difficile infection, revealed in this and
other recent studies, also opens possibilities for application
of this approach to other gastrointestinal disorders. Condi-
tions such as inflammatory bowel disease and metabolic
disorders including malnutrition and obesity, where the
resident gut microbiota is thought to be a key contributing
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applied with success [47,48].
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